Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington.
Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington; Department of Radiology, University of Washington School of Medicine, Seattle, Washington.
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1349-1356. doi: 10.1016/j.ijrobp.2018.06.017. Epub 2018 Jun 19.
Hepatotoxicity risk in patients with hepatocellular carcinoma (HCC) is modulated by radiation dose delivered to normal liver tissue, but reported dose-response data are limited. Our prior work established baseline [Tc]sulfur colloid (SC) single-photon emission computed tomography (SPECT)/computed tomography (CT) liver function imaging biomarkers that predict clinical outcomes. We conducted a proof-of-concept investigation with longitudinal SC SPECT/CT to characterize patient-specific radiation dose-response relationships as surrogates for liver radiosensitivity.
SC SPECT/CT images of 15 patients with HCC with variable Child-Pugh (CP) status (8 CP-A, 7 CP-B/C) were acquired in treatment position before and 1 month (nominal) after stereotactic body radiation therapy (n = 6) or proton therapy (n = 9). Localized rigid registrations between pre/posttreatment CT to planning CT scans were performed, and transformations were applied to pre/posttreatment SC SPECT images. Radiation therapy doses were converted to EQD2 and Gy RBE (relative biological effectiveness) and binned in 5 GyEQD2 increments within tumor-subtracted livers. Mean dose and percent change (%ΔSC) between pre- and posttreatment SPECT uptake, normalized to regions receiving <5 GyEQD2, were calculated in each binned dose region. Dose-response data were parameterized by sigmoid functions (double exponential) consisting of maximum reduction (%ΔSC), dose midpoint (D), and dose-response slope (α) parameters.
Individual patient sigmoid dose-response curves had high goodness-of-fit (median R = 0.96, range 0.76-0.99). Large interpatient variability was observed, with median (range) in %ΔSC of 44% (20%-75%), D of 13 Gy (4-27 GyEQD2), and α of 0.11 GyEQD2 (0.04-0.29 GyEQD2), respectively. Eight of 15 patients had %ΔSC of 20% to 45%, whereas 7 of 15 had %ΔSC of 60% to 75%, with subgroups made up of variable baseline liver function status and radiation treatment modality. Fatal hepatotoxicity occurred in patients (2 of 15) with low total liver funcation (<0.12) and low D (<7 GyEQD2).
Longitudinal SC SPECT/CT imaging revealed patient-specific variations in dose-response and may identify patients with poor baseline liver function and increased sensitivity to radiation therapy. Validation of this regional liver dose-response modeling concept as a surrogate for patient-specific radiosensitivity has potential to guide HCC therapy regimen selection and planning constraints.
肝细胞癌(HCC)患者的肝毒性风险受给予正常肝组织的放射剂量调节,但报告的剂量-反应数据有限。我们之前的工作建立了基线[Tc]硫胶体(SC)单光子发射计算机断层扫描(SPECT)/计算机断层扫描(CT)肝功能成像生物标志物,可预测临床结果。我们进行了一项具有前瞻性的 SC SPECT/CT 研究,通过纵向 SC SPECT/CT 对患者特异性辐射剂量-反应关系进行特征描述,作为肝放射敏感性的替代指标。
15 例 HCC 患者(8 例 CP-A,7 例 CP-B/C)在接受立体定向体部放射治疗(n=6)或质子治疗(n=9)前和治疗后 1 个月(名义上),在治疗位置采集 SC SPECT/CT 图像。对治疗前/后 CT 与计划 CT 扫描之间进行局部刚性配准,并将变换应用于治疗前/后 SC SPECT 图像。将放射治疗剂量转换为 EQD2 和 Gy RBE(相对生物效应),并在肿瘤减去的肝脏内以 5 GyEQD2 的增量进行分组。在每个分组剂量区域中,计算治疗前/后 SPECT 摄取之间的平均剂量和(%ΔSC)变化,以相对于接受<5 GyEQD2 的区域进行归一化。使用由最大减少(%ΔSC)、剂量中点(D)和剂量反应斜率(α)参数组成的 sigmoid 函数(双指数)对剂量-反应数据进行参数化。
个体患者的 sigmoid 剂量-反应曲线具有较高的拟合优度(中位数 R=0.96,范围 0.76-0.99)。观察到患者间存在较大的变异性,%ΔSC 的中位数(范围)为 44%(20%-75%),D 的中位数(范围)为 13 Gy(4-27 GyEQD2),α的中位数(范围)为 0.11 GyEQD2(0.04-0.29 GyEQD2)。15 例患者中有 8 例的%ΔSC 为 20%-45%,15 例中有 7 例的%ΔSC 为 60%-75%,其中亚组由不同的基线肝功能和放射治疗方式组成。2 例(15 例患者中的 2 例)患者总肝功能<0.12,D<7 GyEQD2,发生致命性肝毒性。
纵向 SC SPECT/CT 成像显示了剂量-反应的患者特异性变化,可能识别出基线肝功能较差和对放射治疗更敏感的患者。验证这种区域性肝剂量-反应建模概念作为患者特异性放射敏感性的替代指标,有可能指导 HCC 治疗方案的选择和规划限制。